pembrolizumab
merck
['key,note,716', 'melanoma', 'pembro', 'keynote-716']
final dmfs in keynote-716 (adj pembro vs placebo in iib or iic melanoma) continues to show benefit with pembro, whether iib or c take home: adj io must be offered to all iib and iic based on these data, although not all pts will take tx presented by #asco23 
Melanoma and high risk skin cancer medical oncologist. Studying hereditary and somatic genomics. CA explant in OH. (IO!) Sports fan, geek, and mommy. Tweets=me.